When COVID-19 exploded around the world, in-progress neurodegenerative disease trials – as well as studies preparing to launch – were faced with a sudden and unexpected challenge: how to adapt their approach with the least disruption possible.
If your study is struggling to reinvent its tactics in the face of COVID-19, read this eBook to find out how to overcome challenges in:
- Safety assessments
- Staff training
- Budget control
- Patient risk management
- and more